Personnel Moves Archives - Page 41 of 42

CHF Solutions announces new president, COO

CHF Solutions (NSDQ:CHFS) recently announced that it has promoted Nestor Jaramillo Jr. to the president and COO spot at the company.

Jaramillo’s promotion was effective July 1.

Jaramillo has been at the Eden Prairie, Minn.-based fluid overload treatment developer since May 2019, focusing on commercial growth.

“Nestor has had a strong impact on our commercial success over the last 14 months,” said CHF Solutions CEO John Erb.

“Under Nestor’s leadership, we have expanded our strategy into critical care and pediatrics, including the recent launch of the Aquadex SmartFlow system for use in adult and pediatric patients weighing over 20 kg. I look forward to continuing to work with Nestor as the company improves the lives of patients suffering from fluid overload,” Erb said in a June 25 news release.

Before CHF, Jaramillo was president and CEO of Innerspace Neuro Solutions, a commercial-stage medtech company that developed, manufacture…

VisionCare names new CEO

Visual prosthetic device developer VisionCare announced today that Thomas Ruggia has been appointed as its new CEO, effective today.

Saratoga, Calif.-based VisionCare’s previous CEO and executive chairman of the board, Wolfgang Tolle, left the company to focus on new opportunities, according to a news release.

“We’re thrilled to welcome Tom to VisionCare,” VisionCare CEO Richard Powers said in a news release. “His nearly 20 years of ophthalmology business experience means he has a comprehensive and nuanced understanding of the health care environment in the U.S. and abroad, as well as significant experience in the development and commercialization of vision products with differing regulatory and pricing structures.

“Tom brings new energy to VisionCare at a pivotal time when we are poised to expand the reach and appeal of the CentraSight treatment program.”

Ruggia previously spent five years at Johnson & Johnson, most re…

Former Eli Lilly researcher joins Bigfoot Biomedical as chief medical officer

Bigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer, the diabetes treatment tech company said today.

Malone, an endocrinologist specializing in diabetes, also spent 12 years in clinical practice.

Get the full story on our sister site Drug Delivery Business News.

Inspire Medical names Ebeling as new COO

Obstructive sleep apnea therapy developer Inspire Medical Systems (NYSE:INSP) announced today that it appointed industry veteran Phil Ebeling as its new COO.

The company’s new COO is taking on responsibilities including oversight and leadership of operations, quality assurance, clinical research, regulatory affairs and business development activities, according to a news release.

Ebeling most recently served as VP & chief technology officer at Abbott (NYSE:ABT) after it acquired St. Jude Medical. He served for 10 years total between the two companies as a member of the executive team and corporate officer with both. He also spent 12 years in multiple senior positions at Boston Scientific (NYSE:BSX).

“I am thrilled to join the dynamic team at Inspire during this exciting period of robust growth highlighted by the recent positive advancements in reimbursement,” Ebeling said in the news release. “The ongoing development of Inspire therapy and futu…

Inspire Medical raises $10.7m, names new COO

Inspire Medical Systems (NYSE:INSP) announced today that it raised $10.7 million and named Phil Ebeling as its new chief operating officer.

According to a news release, Inspire entered into an underwriting agreement on June 3 with A.G.P./Alliance Global Partners in the offering of more than 7.6 million units consisting of one share of Inspire’s common stock and one Series F warrant to purchase a share, plus nearly 14.6 million pre-funded units that included one pre-funded warrant and one Series F warrant.

Underwriters also had a 45-day option to purchase up to an additional 3.3 million shares of common stock at 45¢ per share and/or up to 3.3 million additional Series F warrants. The offering closed on June 5 with the underwriter option exercised nearly in full, yielding gross proceeds of $11.5 million, turning into net proceeds worth $10.7 million.

The obstructive sleep apnea (OSA) therapy developer intends to use the net proceeds for research and …

B. Braun’s top North American executive to retire

Caroll H. Neubauer will retire at the end of August as the head of B. Braun’s North America operations.

B. Braun announced today that Caroll H. Neubauer will retire at the end of August after 24 years leading the Melsungen, Germany–based medical and drug delivery device giant’s North America operations.

Jean-Claude Dubacher, a former Johnson & Johnson and Abbott executive who already took over Neubauer’s role as CEO of B. Braun Medical at the start of the year, has now also assumed Neubauer’s position as chair and CEO of B. Braun of America, effective June 1. Neubauer will stay on until Aug. 31 as executive director of B. Braun of America.

Get the full story on our sister site MassDevice.

B. Braun’s top North American executive to retire

Caroll H. Neubauer will retire at the end of August as the head of B. Braun’s North America operations.

B. Braun announced today that Caroll H. Neubauer will retire at the end of August after 24 years leading the Melsungen, Germany–based medical and drug delivery device giant’s North America operations.

Jean-Claude Dubacher, a former Johnson & Johnson and Abbott executive who already took over Neubauer’s role as CEO of B. Braun Medical at the start of the year, has now also assumed Neubauer’s position as chair and CEO of B. Braun of America, effective June 1. Neubauer will stay on until Aug. 31 as executive director of B. Braun of America.

Based in Bethlehem, Pa., B. Braun of America includes B. Braun Medical (also in Bethlehem), B. Braun Interventional Systems, Aesculap and Central Admixture Pharmacy Services (CAPS). Under Neubauer’s leadership, the North America ope…

Nevro appoints MacLeod as CFO

Nevro (NYSE:NVRO) announced today that it appointed Roderick MacLeod as its new chief financial officer, effective June 15.

MacLeod will succeed current CFO Andrew Galligan, who is set to retire, but will remain on with the company during a transition period as MacLeod takes over. Galligan spent 10 years at Nevro, according to a news release.

“I’m very pleased to join Nevro and I view this as an exciting opportunity to continue to build a great company while helping patients who suffer from chronic pain,” MacLeod said in the release. “I look forward to working closely with Keith and the rest of the Nevro team to execute on the Company’s growth strategy.”

Prior to taking on this new role, the 25-year veteran of financial and executive leadership roles in healthcare and technology spent 16 years at Stryker (NYSE:SYK). He served as VP of finance at Stryker Endoscopy and, before that, controller for the same division. Mac…

3M appoints Patolawala as new CFO

3M (NYSE:MMM) announced today that it appointed Monish Patolawala as its new senior VP and chief financial officer, effective July 1.

Patolawala is set to succeed Nick Gangestad, who announced that he is retiring, but will stay on through July 31 in an effort to ensure an orderly transition. Gangestad spent 35 years with 3M, according to a news release.

Currently the CFO at General Electric Healthcare (NYSE:GE), Patolawala has been with GE since 1994, also recently serving as VP of operational transformation at the company.

“I am pleased to welcome Monish to our leadership team,” 3M chairman & CEO Mike Roman said in the news release. “His deep and extensive experience in leading the financial operations of industrial and healthcare businesses – as well as driving operational changes – will make an immediate impact as we manage through the current economic challenges and continue to position 3M for the future. I am confident Monish will provide strong…

Arterys raises $28m Series C

Arterys, a medical imaging software developer for clinical AI products, announced today that it raised $28 million in a Series C financing round.

Benslie Investment Group and Temasek Holdings led the funding, while Fosun, Revelation Partners, Emergent Medical Partners and Varian Medical Systems participated as well.

San Francisco-based Arterys said in a news release that it intends to use the funds to broaden its ecosystem, which includes a broad set of partners on its new marketplace that utilizes its cloud platform.

Much focus will gear toward accelerating partners’ efforts to bring new, clinical-grade AI applications to providers by extending the Arterys technology platform to application partners so they can integrate AI into their workflows, the company said.

Additionally, Arterys appointed co-founder John Axerio-Cilies as its acting CEO. According to a previous press release, Axerio-Cilies previously held the role of chief tech…

Iradimed CEO resigns; replacement named

Iradimed (NSDQ:IRMD) announced today that it appointed former president and CEO Roger Susi to resume the roles 10 months after he stepped down.

On July 29, 2019, the Winter Springs, Fla.-based MRI-compatible medical device developer announced that Susi would continue as the company’s chairman and chief technology officer, while Leslie McDonnell would assume the roles of president and CEO.

However, McDonnell separated from the company effective yesterday, according to a news release, leading to the reappointment of Susi, who had led the company for 27 years from its founding before stepping down last year.

“I look forward to resuming as the company’s president and CEO and would like to thank Ms. McDonnell for her contributions during her tenure,” Susi said in the release. “I remain optimistic about our future and am excited to lead Iradimed through its next stages of growth.” In McDonnel’s last quarter as president and CEO, Iradimed increa…

Siren raises $11.8m Series B

Siren, a developer of smart textiles with remote patient monitoring applications, announced today that it raised $11.8 million in a Series B financing.

The San Francisco-based medical device company had its funding round led by Anathem Ventures, with participation from existing investors DCM, Khosla Ventures, 500 Startups and Peter Thiel’s Founders Fund. Additionally, DCM partner Jason Krikorian will join Siren’s board and Anathem managing partner Crystal McKellar will join Siren as an advisor.

Siren’s latest round of funding adds nearly $12 million to the $22 million it has already raised across three funding rounds since its founding in 2015, according to a news release. The company noted in the release that the finances it has secured is helping it to position itself for commercial expansion.

The company’s portfolio includes a temperature-monitoring sock capable of connecting wirelessly to a software application, allowing podi…